Targeting specific immune cells to reduce inflammation in atherosclerosis
Official title: Engineered Cytokines Targeting Lipid-Laden Macrophages
Funded at Northwestern University · NIH-10723576 · Data updated 2026-11-12
This study is testing a new treatment for atherosclerosis that uses specially designed proteins to help calm down the inflammation caused by certain immune cells in your body, aiming to improve heart health for people dealing with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | August 21, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $160,000 |
| NIH project number | 1K22AI177518-01 |
| Project ID | NIH-10723576 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with atherosclerosis or those exhibiting high levels of inflammation related to lipid metabolism.
✕Less likely to help
Patients who do not have atherosclerosis or related inflammatory conditions may not benefit from this research.
What this research studies
This research investigates a novel approach to treat atherosclerosis by engineering cytokines that specifically target lipid-laden macrophages, which are key players in the inflammatory process of this disease. The study utilizes a unique protein fusion that combines an antibody fragment that binds to low-density lipoprotein (LDL) with an anti-inflammatory cytokine, IL-10. By delivering this engineered cytokine directly to inflamed macrophages, the goal is to reduce inflammation and improve outcomes for patients with atherosclerosis. The research will explore how these engineered cytokines work at the molecular level to suppress inflammation in affected tissues.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for atherosclerosis, potentially reducing cardiovascular events and improving patient quality of life.
How similar studies have gone: Previous research has shown promise in targeting macrophages for immunomodulation, suggesting that this approach could be a significant advancement in treating inflammatory diseases.
Where this research is happening
-
Northwestern University
Chicago, United States Active
Researchers
- Principal investigator: Volpatti, Lisa R — Northwestern University
- Study coordinator: Volpatti, Lisa R
Related research
Other NIH-funded projects on the same topics.
-
Understanding how language and social communication work in FMR1-related autism risks
A small, patient-friendly study looks at why people with FMR1 gene changes may have pragmatic language difficulties, which are common in autism and related conditions.
-
Transformative patient navigation interventions for cancer care in diverse communities
A nationwide cancer center is testing new, community-driven ways to help people with cancer navigate care and information, especially where access is challenging.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Point-of-care AQP4 antibody test to diagnose NMO in low-resource settings
A low-cost, mail-in dried-blood-spot test is being studied to diagnose neuromyelitis optica in people who live far from big labs or in low-income countries.
-
Supercomputer models to understand how human motor signals reach muscles
A computer-based effort uses human motoneuron models to figure out the exact mix of inputs that control muscle activity.
-
Negotiation training to help Alzheimer’s caregivers communicate with care teams
A program called NegotiAge helps families caring for people with Alzheimer’s disease learn better negotiation skills to talk with doctors, insurers, and other caregivers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.